![]() Millennium Management LLC now owns 1,213,394 shares of the company’s stock valued at $44,216,000 after acquiring an additional 999,487 shares during the period. Millennium Management LLC lifted its stake in shares of 10x Genomics by 467.3% during the fourth quarter. now owns 9,156,992 shares of the company’s stock valued at $696,572,000 after acquiring an additional 1,138,358 shares during the period. lifted its stake in shares of 10x Genomics by 14.2% during the first quarter. Several other institutional investors have also bought and sold shares of TXG. State of New Jersey Common Pension Fund D’s holdings in 10x Genomics were worth $2,757,000 at the end of the most recent quarter. The institutional investor owned 49,416 shares of the company’s stock after selling 13,805 shares during the quarter. ( NASDAQ:TXG – Free Report) by 21.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). "That's certainly something we seriously think about and keep in our sights."Ĭrutchfield added that among the customers already ordering Visium reagent kits, 20 percent were new to 10x, a number he said he expects to grow over time.State of New Jersey Common Pension Fund D decreased its stake in 10x Genomics, Inc. "There's no fundamental reason why the technology can't work with FFPE," Saxonov said. At launch, Visium will only work with fresh-frozen tissue sections. During the Q&A portion of the call, he told analysts that the firm is looking towards getting Visium to work with formalin-fixed, paraffin-embedded (FFPE) samples, the most prevalent sample type found in clinical pathology. ![]() Saxonov also said during the call that the firm is on track to begin shipping its Visium Spatial Gene Expression platform before the end of the year. Saxonov also didn't provide more detail about the instrument rollout and whether it would be available to early-access users before the "early 2020" timeframe. Chief Commercial Officer Brad Crutchfield said, "It's a niche product that I think you're going to have a higher pull-through in there to justify the capital expenditure." The firm is investing heavily in R&D: in the third quarter, the firm's spending in that area doubled to $22.2 million.ġ0x officials did not say how much Chromium Connect would cost. Whether 10x plans to support preparation of other types of assay kits from other suppliers is unclear.Ĭhromium Connect is one of several products in 10x's pipeline. The instrument will also support plate preparation for Kapa Library Quantification kits from Roche, for quality control, although that assay requires a quantitative PCR instrument, which the Chromium Connect does not provide. Initially, Chromium Connect will only be compatible with the Next GEM Single Cell Gene Expression v3.1 assay kit, but a 10x spokesperson said the firm will add additional assays over time. The instrument comes with a touch-screen computer and is compatible with laboratory information management systems for experiment tracking and error logging. It can run up to eight samples per run, using automation-specific reagents and consumables. Chromium connect is designed for "pharma-oriented workflows," he said, but could also be useful for high-throughput labs and service providers.Īccording to a product brochure posted on 10x's website, Chromium Connect will take in cell suspensions and put out single-cell libraries ready for Illumina sequencing with less than 1 hour of hands-on time. "It's walk-away automation," he said in a follow-up interview. ![]() On a conference call last week following the release of the firm's third quarter financial results, Saxonov said the Chromium Connect, which combines the Chromium Controller with automated liquid handling, a thermal cycler, and a magnetic plate for bead purification, will be coming out early next year. NEW YORK – 10x Genomics will soon be releasing a fully automated version of its Chromium Controller single-cell library preparation instrument, CEO Serge Saxonov said. Advances in Clinical Genomics Profiling. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |